<DOC>
	<DOCNO>NCT01388647</DOCNO>
	<brief_summary>This study evaluate safety efficacy eribulin combination carboplatin trastuzumab neoadjuvant set subject human epidermal growth factor receptor ( HER ) 2 positive clinically stage IIA IIIB . The study regimen administer every 3 week total 6 cycle follow definitive surgery .</brief_summary>
	<brief_title>Study Neoadjuvant Carboplatin , Eribulin Trastuzumab Operable HER2 Positive Breast Cancer</brief_title>
	<detailed_description>During Phase I , eribulin dose assign upon study enrollment . The maximum tolerated dose ( MTD ) determine Phase I dose used Phase II . Eribulin administer intravenously ( IV ) 2 5 minute Days 1 8 cycle . Carboplatin area curve ( AUC ) 6 administer IV 15 30 minute Day 1 cycle . Trastuzumab administer IV infusion Day 1 cycle . A load dose 8 mg/kg trastuzumab administer 90 minute Cycle 1 Day 1 . Then , maintenance dose 6 mg/kg trastuzumab administer 30 90 minute Day 1 Cycles 2 - 6. eribulin : During Phase I , eribulin dose assign upon study enrollment . The maximum tolerated dose ( MTD ) determine Phase I dose used Phase II . Eribulin administer intravenously ( IV ) 2 5 minute Days 1 8 cycle . carboplatin : Carboplatin area curve</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Written inform consent Females ; 18 year age great Histologically proven invasive breast cancer American Joint Committee Cancer ( AJCC ) clinical stage IIA IIIB Tumor size great 10 millimeter HER2 positive Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Estrogen receptor ( ER ) positive negative Ejection fraction great equal low limit normal institution echocardiogram ( ECHO ) multiple gated acquisition scan ( MUGA ) Less equal Grade 1 neuropathy accord Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 Planned lumpectomy mastectomy Eligible radiation therapy No prior treatment invasive breast cancer Adequate organ system function per protocol determine within 7 day prior first dose study treatment Women childbearing potential must negative pregnancy test within 7 day prior first dose study treatment must agree use adequate contraception method study treatment minimum 6 month follow trastuzumab discontinuation Female subject lactate discontinue nursing prior first dose study treatment refrain nursing throughout treatment period Fine needle cytology without histologic evidence invasive breast cancer Inflammatory breast cancer AJCC clinical stage T1ab breast cancer ( primary tumor less equal 10 millimeter ) Evidence metastatic disease HER2 negative Ejection fraction less low limit normal institution ECHO MUGA Corrected QT interval great 480 millisecond Preexisting cardiac dysfunction Prior history invasive cancer within past 3 year Synchronous bilateral breast cancer Preexisting CTCAE v4.0 Grade 2 great neuropathy Hypersensitivity halichondrin B halichondrin B chemical derivative History severe allergic reaction cisplatin platinum contain compound , mannitol Mild , moderate , severe hepatic impairment Moderate severe renal impairment Hypokalemia hypomagnesemia correct prior first dose study treatment Organ allografts require immunosuppression Known positive human immunodeficiency virus ( HIV ) status Prior major surgery within 28 day prior first dose study treatment and/or presence nonhealing wound , fracture , ulcer Minor surgery radiation therapy within 14 day prior first dose study treatment Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Neoadjuvant Treatment</keyword>
	<keyword>HER-2 Positive Breast Cancer</keyword>
</DOC>